ZNTL Zentalis Pharmaceuticals Inc

Price (delayed)

$4.01

Market cap

$284.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.33

Enterprise value

$287.08M

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of ...

Highlights
Zentalis Pharmaceuticals's quick ratio has increased by 28% from the previous quarter and by 28% YoY
Zentalis Pharmaceuticals's EPS has increased by 26% from the previous quarter and by 22% YoY

Key stats

What are the main financial stats of ZNTL
Market
Shares outstanding
71.01M
Market cap
$284.76M
Enterprise value
$287.08M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
7.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.08
Earnings
Revenue
$40.56M
EBIT
-$219.53M
EBITDA
-$218.17M
Free cash flow
-$211.14M
Per share
EPS
-$3.33
Free cash flow per share
-$2.98
Book value per share
$6.47
Revenue per share
$0.57
TBVPS
$7.81
Balance sheet
Total assets
$557.48M
Total liabilities
$98.71M
Debt
$42.62M
Equity
$458.77M
Working capital
$449.01M
Liquidity
Debt to equity
0.09
Current ratio
9.19
Quick ratio
8.97
Net debt/EBITDA
-0.01
Margins
EBITDA margin
-537.9%
Gross margin
100%
Net margin
-539.8%
Operating margin
-639.4%
Efficiency
Return on assets
-37.8%
Return on equity
-46.1%
Return on invested capital
-49.2%
Return on capital employed
-43.7%
Return on sales
-541.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZNTL stock price

How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
8.38%
1 week
0.75%
1 month
-15.58%
1 year
-84.69%
YTD
-73.53%
QTD
-1.96%

Financial performance

How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
$40.56M
Gross profit
$40.56M
Operating income
-$259.32M
Net income
-$218.96M
Gross margin
100%
Net margin
-539.8%
Zentalis Pharmaceuticals's net income has increased by 25% from the previous quarter and by 9% YoY
The operating income has grown by 13% from the previous quarter but it has contracted by 11% YoY

Growth

What is Zentalis Pharmaceuticals's growth rate over time

Valuation

What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.62
P/S
7.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.08
Zentalis Pharmaceuticals's EPS has increased by 26% from the previous quarter and by 22% YoY
The P/B is 88% less than the 5-year quarterly average of 5.1 and 78% less than the last 4 quarters average of 2.8
ZNTL's equity is up by 19% YoY and by 4.9% from the previous quarter

Efficiency

How efficient is Zentalis Pharmaceuticals business performance
ZNTL's ROIC is up by 28% since the previous quarter and by 8% year-on-year
The ROE rose by 28% since the previous quarter and by 18% year-on-year
The ROA is up by 27% since the previous quarter and by 17% year-on-year

Dividends

What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZNTL.

Financial health

How did Zentalis Pharmaceuticals financials performed over time
The current ratio has increased by 28% from the previous quarter and by 26% YoY
Zentalis Pharmaceuticals's quick ratio has increased by 28% from the previous quarter and by 28% YoY
The company's debt is 91% lower than its equity
The debt to equity has declined by 25% year-on-year and by 10% since the previous quarter
ZNTL's equity is up by 19% YoY and by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.